Fig. 3From: Efficacy and safety of tyrosine kinase inhibitors with thoracic radiotherapy for patients with oncogene-mutated non-small cell lung cancer: a meta-analysisAssessment of median Progression Free Survival (mPFS) of first-line treatmentBack to article page
